Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party
| Autor: | Rose Marie Hamladji, Arnon Nagler, Moshe Yeshurun, Didier Blaise, Maud D’Aveni-Piney, Ibrahim Yakoub-Agha, Marie-Thérèse Rubio, José Luis Díez-Martín, Hakan Ozdogu, Stella Santarone, Bipin N. Savani, Miguel A. Sanz, Mohamad Mohty, Myriam Labopin, Etienne Daguindeau, Giuseppe Irrera, Carlos Richard |
|---|---|
| Přispěvatelé: | Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Service d'Hématologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Centre de Recherche Saint-Antoine (UMRS893), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie - Paris 6 (UPMC), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service Hématologie Greffe de Moëlle [Alger, Algeria], Centre Pierre et Marie Curie [Alger, Algeria], Servicio de Hematologia [Valencia, Spain], Hospital La Fe [Valencia, Spain], Programme de Transplantation and Therapie Cellulaire [Marseille], Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Hematology Research Laboratory [Adana, Turkey] (Hematology Division - BMT Unit), Başkent University Hospital [Adana, Turkey], Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Servicio de Hematología-Hemoterapia [Santander, Spain], Marqués de Valdecilla University Hospital [Spain], Department of Hematology [Pescara, Italy], Bone Marrow Transplant Center [Pescara, Italy]-Ospedale Civile - BMT Center [Pescara, Italy], Azienda Ospedaliera [Calabria, Italy], Centro Unico Regionale Trapianti [Calabria, Italy], Service des Maladies du Sang [Lille] (RCP HÉMATOLOGIE GREFFE), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Hôpital Huriez, Hematology and BMT Department [Petach-Tikva, Israel], Rabin Medical Center - Beilinson and Hasharon Hospitals [Petach-Tikva, Israel], Sección de Transplante de Medula Osea [Madrid, Spain], Gregorio Marañón Hospital [Madrid, Spain], Vanderbilt University Medical Center [Nashville], Vanderbilt University [Nashville], Division of Hematology [Tel Hashomer, Israel], The Chaim Sheba Medical Center [Tel Hashomer, Israel], BMC, BMC, Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut Paoli-Calmettes |
| Rok vydání: | 2017 |
| Předmět: |
Male
Oncology Cancer Research Transplantation Conditioning T-Lymphocytes [SDV]Life Sciences [q-bio] Graft vs Host Disease Graft-versus-host disease In vivo T cell depletion 0302 clinical medicine HLA Antigens Cumulative incidence ComputingMilieux_MISCELLANEOUS Acute leukemia Hematopoietic Stem Cell Transplantation Myeloid leukemia lcsh:Diseases of the blood and blood-forming organs Hematology Middle Aged lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens 3. Good health Fludarabine [SDV] Life Sciences [q-bio] Leukemia Myeloid Acute HLA-matched related donor Treatment Outcome Histocompatibility 030220 oncology & carcinogenesis Female Leukocyte Reduction Procedures Vidarabine medicine.drug Adult medicine.medical_specialty Adolescent lcsh:RC254-282 Lymphocyte Depletion Young Adult 03 medical and health sciences Internal medicine medicine Humans Busulfan Molecular Biology Aged Antilymphocyte Serum Retrospective Studies Acute myeloid leukemia lcsh:RC633-647.5 business.industry Research Myeloablative Agonists medicine.disease Allogeneic stem cell transplantation Transplantation Regimen GRFS Relapse incidence Immunology business 030215 immunology |
| Zdroj: | Journal of Hematology and Oncology Journal of Hematology and Oncology, BioMed Central, 2016, 10 (1), pp.31. ⟨10.1186/s13045-016-0389-4⟩ Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-11 (2017) Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid Journal of Hematology and Oncology, 2016, 10 (1), pp.31. ⟨10.1186/s13045-016-0389-4⟩ Journal of Hematology & Oncology Journal of Hematology & Oncology, CAHON, 2017, 10 (1), ⟨10.1186/s13045-016-0389-4⟩ JOURNAL OF HEMATOLOGY & ONCOLOGY r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname |
| ISSN: | 1756-8722 |
| Popis: | Background The impact of the use of anti-thymocyte globulin (ATG) in allogeneic stem cell transplantation performed with HLA-identical sibling donors following fludarabine and 4 days intravenous busulfan myeloablative conditioning regimen has been poorly explored. Methods We retrospectively analyzed 566 patients who underwent a first HLA-identical allogeneic stem cell transplantation with this conditioning regimen for acute myeloid leukemia in first complete remission between 2006 and 2013 and compared the outcomes of 145 (25.6%) patients who received ATG (ATG group) to 421 (74.4%) who did not (no-ATG group). The Kaplan-Meier estimator, the cumulative incidence function, and Cox proportional hazards regression models were used where appropriate. Results Patients in the ATG group were older, received more frequently peripheral blood stem cell grafts from older donors, and were transplanted more recently. With a median follow-up of 19 months, patients in the ATG group had reduced 2-year cumulative incidence of chronic graft-versus-host disease (GVHD) (31 vs. 52%, p = 0.0002) and of its extensive form (8 vs. 26%, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|